Inspire Medical Systems, Inc. (“Inspire”) announced today that Cigna, one of the leading health plans in the United States, will provide coverage for the Company’s Inspire therapy (hypoglossal nerve neurostimulation), effective June 15, 2020. Cigna Corporation is a global health service company that provides health insurance coverage for approximately 16 million members in the U.S.
“We are very pleased to receive this positive coverage decision from Cigna. As health plans continue to update their coverage policies to include Inspire therapy, an increasing number of patients and physicians will have access to our innovative therapy,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. “With the addition of Cigna, we now have 54 coverage policies, representing over 180 million members, that cover Inspire therapy, compared to 83 million members just one year ago.”
In addition to the 54 commercial coverage policies, Inspire therapy will soon have Medicare coverage across the entire United States. The final Medicare Administrative Contractor (“MAC”), Palmetto GBA, LLC (“Palmetto”), announced its final Local Coverage Decision (“LCD”) policy date release of June 21, 2020, for covering Inspire therapy.
“Importantly, the Cigna policy and all of the Medicare LCD policies became, or will become, effective during the COVID-19 pandemic, and we anticipate that these collective policies position us well to further accelerate growth once the impact of COVID-19 subsides,” concluded Mr. Herbert.
Under its policy, Cigna considers Inspire’s U.S. Food and Drug Administration (“FDA”) approved hypoglossal nerve neurostimulation device to be medically necessary for the treatment of moderate to severe OSA when specified criteria are met, including a previous attempt at continuous positive airway pressure (“CPAP”) treatment.
Source: Inspire Medical Systems